Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-709 in advanced malignant tumors
NCT07016490Phase 1Recruiting
- Sponsor
- 3SBio
- Start
- Jun 2025
- Primary completion
- Sep 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SSGJ-709 in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), Esophageal Squamous Cell Carcinoma (ESCC) and 7 more, sponsored by 3SBio. Primary endpoints: Dose-Limiting Toxicity at 21 days and Treatment-Emergent Adverse Events at 1 year. Started Jun 2025; status: recruiting.
02
Drugs
SSGJ-709
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)esophageal adenocarcinoma (EAC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT07016490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07016490.